Atea Pharmaceuticals Inc.
| NYSE: AVIR | Healthcare / Biotechnology / USA |
| 2.95 | +0.0500 | +1.72% | Vol 466.77K | 1Y Perf -36.68% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 2.91 | ASK | 3.05 | ||
| Open | 2.91 | Previous Close | 2.90 | ||
| Pre-Market | - | After-Market | 3.02 | ||
| - - | 0.07 2.37% |
| Target Price | 9.00 | Analyst Rating | Hold 3.17 | |
| Potential % | 205.09 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★★ 71.22 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★★ 77.92 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 7.63 | Earnings Rating | — | |
| Market Cap | 246.13M | Earnings Date | 8th Nov 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.25 | |
| Beta | 0.18 |
Today's Price Range 2.913.02 | 52W Range 2.775.19 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.57% | ||
| 1 Month | -5.84% | ||
| 3 Months | -13.69% | ||
| 6 Months | -38.03% | ||
| 1 Year | -36.68% | ||
| 3 Years | -91.58% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 5.73 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | 4.66 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | 4.81 | |||
Return on invested Capital Q | -1.66 | |||
Return on invested Capital Y | 19.24 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 14.20 | ||||
| 0.59 | ||||
| 1.99 | ||||
| 1.80 | ||||
| -3.90 | ||||
| -2.07 | ||||
| 0.59 | ||||
| 7.96 | ||||
| -270 227 000.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 42.80 | ||||
| 43.60 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| 15.80 | ||||
| 15.90 | ||||
| - | ||||
| 18.55 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.47 | -0.34 | 27.66 |
| Q01 2023 | -0.51 | -0.43 | 15.69 |
| Q04 2022 | -0.45 | -0.41 | 8.89 |
| Q03 2022 | -0.44 | -0.10 | 77.27 |
| Q02 2022 | -0.52 | -0.38 | 26.92 |
| Q01 2022 | -0.58 | -0.51 | 12.07 |
| Q04 2021 | 0.33 | 1.34 | 306.06 |
| Q03 2021 | -0.05 | -0.34 | -580.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.46 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 466.77K |
| Shares Outstanding | 83.44K |
| Shares Float | 65.41M |
| Trades Count | 3.55K |
| Dollar Volume | 1.38M |
| Avg. Volume | 381.91K |
| Avg. Weekly Volume | 359.67K |
| Avg. Monthly Volume | 394.91K |
| Avg. Quarterly Volume | 391.17K |
Atea Pharmaceuticals Inc. (NYSE: AVIR) stock closed at 2.9 per share at the end of the most recent trading day (a 0.69% change compared to the prior day closing price) with a volume of 445.59K shares and market capitalization of 246.13M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. Atea Pharmaceuticals Inc. CEO is Jean-Pierre Sommadossi.
The one-year performance of Atea Pharmaceuticals Inc. stock is -36.68%, while year-to-date (YTD) performance is -39.71%. AVIR stock has a five-year performance of %. Its 52-week range is between 2.765 and 5.19, which gives AVIR stock a 52-week price range ratio of 7.63%
Atea Pharmaceuticals Inc. currently has a PE ratio of 14.20, a price-to-book (PB) ratio of 0.59, a price-to-sale (PS) ratio of 1.99, a price to cashflow ratio of 1.80, a PEG ratio of -, a ROA of 4.66%, a ROC of 4.81% and a ROE of 5.73%. The company’s profit margin is 18.55%, its EBITDA margin is 15.90%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Atea Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Atea Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Atea Pharmaceuticals Inc. is Hold (3.17), with a target price of $9, which is +205.09% compared to the current price. The earnings rating for Atea Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Atea Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Atea Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.95, ATR14 : 0.14, CCI20 : -69.80, Chaikin Money Flow : -0.16, MACD : -0.06, Money Flow Index : 54.85, ROC : -11.85, RSI : 44.49, STOCH (14,3) : 21.26, STOCH RSI : 0.60, UO : 43.04, Williams %R : -78.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Atea Pharmaceuticals Inc. in the last 12-months were:
Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
CEO: Jean-Pierre Sommadossi
Telephone: +1 857 284-8891
Address: 125 Summer Street, Boston 02110, MA, US
Number of employees: 19
